GLENMARK — Glenmark Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- IN₹304.58bn
- IN₹346.99bn
- IN₹115.83bn
Annual cashflow statement for Glenmark Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | — | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 12,580 | 10,961 | 13,825 | 14,412 | 8,685 |
| Depreciation | |||||
| Non-Cash Items | -1,740 | 2,191 | 2,013 | 3,004 | 8,607 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3,063 | -3,399 | -8,961 | -11,197 | -17,144 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 13,242 | 13,924 | 11,312 | 11,087 | 6,261 |
| Capital Expenditures | -12,394 | -9,324 | -7,748 | -7,901 | -6,078 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 5,404 | 1,489 | 995 | 4,568 | 793 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -6,990 | -7,835 | -6,752 | -3,333 | -5,285 |
| Financing Cash Flow Items | -3,016 | -3,015 | -2,936 | -3,079 | -4,643 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -7,387 | -4,447 | -4,418 | -5,205 | -775 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -2,971 | 1,740 | 278 | 2,724 | 325 |